<DOC>
	<DOCNO>NCT02453477</DOCNO>
	<brief_summary>This phase I/II study evaluate safety efficacy autologous hematopoietic stem cell genetically modify GLOBE lentiviral vector encode human beta-globin gene treatment patient affected transfusion dependent beta-thalassemia</brief_summary>
	<brief_title>Gene Therapy Transfusion Dependent Beta-thalassemia</brief_title>
	<detailed_description>Both adult pediatric patient treat genetically modify autologous hematopoietic stem cell collect mobilized peripheral blood ( bone marrow patient &lt; 8 year case mobilization feasible ) transduce GLOBE lentiviral vector encode human beta-globin gene . This study enroll 10 patient allocate 3 group , accord age condition regimen : 1 . 3 adult ( ≥18 year ) condition treosulfan thiotepa 2 . 3 elderly child ( 8-17 year ) condition treosulfan thiotepa 3 . 4 young child ( 3-7 year ) condition busulfan Enrolment start adult patient . Pediatric patient include evidence preliminary safety biological efficacy show least 2 adult . Patients include regardless beta globin gene mutation , provide adequate cardiac , renal , hepatic pulmonary function demonstrate . Patients severe iron overload exclude well patient active viral infection . Pediatric patient enrol absence human leukocyte antigen ( HLA ) -identical sibling suitable 10/10 match unrelated donor . The treated patient follow 2 year . After completion 2 year follow , patient enrol long term follow study follow least additional 6 year .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Written inform consent Transfusiondependent betathalassemia ( genotype ) . Transfusion dependence define receive ≥ 8 transfusion blood per year minimum 2 year . Karnofsky Index Lansky &gt; 80 % Age ≥ 3 year &lt; 65 year Adequate cardiac , renal , hepatic pulmonary function evidence : Left ventricular ejection fraction ( LVEF ) great 45 % echo normal ECG presence abnormality significant cardiac disease . Absence severe pulmonary hypertension Diffusing capacity lung carbon monoxide ( DLCO ) &gt; 50 % forced expiratory volume 1 sec ( FEV1 ) force expiratory vital capacity ( FVC ) &gt; 60 % predict ( non cooperative : pulse oximetry &gt; 95 % room air ) Serum creatinine &lt; 1.5 upper limit normal Absentmildmoderate liver iron overload T2*MRI ( less 12 month enrolment ) Absentmildmoderate cardiac iron overload T2*MRI ( less 12 month enrolment ) Absence severe liver fibrosis cirrhosis fibroscan liver biopsy ( le 12 month enrolment ) Low risk thrombophilic screen negative history significant previous thrombotic event For patient reproductive age , agreement use highly effective adequate method contraception receive treatment phase least 12 month follow drug administration ( include female child bear potential male partner child bear potential ) Good adherence transfusion chelation programme indirect evidence good adherence treatment followup evaluation current trial Availability adequate well documented transfusion history ( least previous 6 month ) availability follow regular transfusion regimen accord guideline provide detailed transfusion record 6 month prior intervention phase Use investigational agent within 4 week prior study enrolment ( within 6 week use longacting agent ) Severe , active viral , bacterial , fungal infection eligibility evaluation Malignant neoplasia ( except local skin cancer cervical intraepithelial neoplasia ) exceptional family history familial cancer syndrome Myelodysplasia , cytogenetic alteration associate neoplasia , serious haematological disorder thalassemia History uncontrolled seizures Other clinical condition judge non compatible procedure and/or treatment Positivity HIV ( serology RNA ) , and/or HbsAg and/or HBV DNA and/or HCV RNA ( negative HCV RNA antiviral treatment ) and/or Treponema Pallidum Mycoplasma active infection Active alcohol substance abuse within 6 month study Pregnancy lactation Previous allogeneic bone marrow transplantation gene therapy For paediatric patient : availability HLAmatched donor ( sibling suitable 10/10 match unrelated donor ) .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Beta thalassemia</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Lentiviral vector</keyword>
</DOC>